Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEN-SURVIVORS: Senolytics for Frailty in Childhood Cancer Survivors
NCT04733534Phase 2Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, quercetin, fisetin in frailty syndrome, sponsored by St. Jude Children's Research Hospital. Started Jun 2022; status: active, not recruiting.
02
Drugs
dasatinibquercetinfisetin
03
Conditions
frailty syndrome
Beyond the preview
Go deeper on NCT04733534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04733534.